BioCentury
ARTICLE | Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

BioCentury’s roundup of preclinical news

May 30, 2020 1:14 AM UTC

Brain cancer CAR T therapy
A McMaster University and University of Toronto team revealed in a Cell Stem Cell paper proof-of-concept data for Empirica Therapeutics’ lead product eCAR-133, a CAR T cell therapy targeting PROM1. Led by Empirica CEO Sheila Singh and CSO Jason Moffat, the researchers showed that intracranial administration of eCAR-133, dubbed CART-133 in the publication, reduced tumor size and extended lifespan in xenograft mouse models of glioblastoma. The company plans to begin in early 2021 clinical trials of eCAR-133 to treat the indication (see “Empirica: Building a New Model for Brain Cancer”).

Tumor microbiome varies by tumor type...